Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionHsbc Holdings Plc
Latest Disclosed Ownership89,619 shares
Latest Disclosed Value $ 29,638,687
Hsbc Holdings Plc ownership in DUL / Alnylam Pharmaceuticals, Inc.

On April 30, 2026 - Hsbc Holdings Plc filed a 13F-HR form disclosing ownership of 89,619 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $25,604,148 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 20, 2026 disclosing 89,517 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.11% during the quarter. The current value of the position is $23,345,750 USD.

Hsbc Holdings Plc has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,619 102 0.11 29,639 -16.92 0.0021
2026-03-20 2025-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 89,517 16,503 22.60 35,675 7.11 0.0182
2026-03-06 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,517 16,503 35,675 0.0016
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,014 -8,734 -10.68 33,306 25.08 0.0184
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 81,748 20,483 33.43 26,627 61.57 0.0160
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,265 -317 -0.51 16,481 13.55 0.0102
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,582 4,712 8.29 14,515 -7.12 0.0084
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,870 2,715 5.01 15,628 18.64 0.0091
2024-08-12 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,155 -19,976 -26.95 13,173 18.96 0.0081
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 74,131 29,932 67.72 11,073 30.75 0.0075
2024-02-12 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,199 9,014 25.62 8,470 35.94 0.0074
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,185 4,508 14.70 6,230 6.93 0.0065
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,677 -8,617 -21.93 5,827 -25.98 0.0059
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,294 6,560 20.04 7,871 1.18 0.0094
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,734 -2,659 -7.51 7,779 8.37 0.0089
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,393 -14,468 -29.02 7,178 -1.32 0.0117
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,861 2,034 4.25 7,274 -7.02 0.0102
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,827 6,487 15.69 7,823 11.39 0.0095
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,340 12,626 43.97 7,023 31.34 0.0065
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,714 1,004 3.62 5,347 14.25 0.0054
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,710 -5,210 -15.83 4,680 1.28 0.0050
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,920 -570 -1.70 4,621 6.11 0.0054
2021-02-25 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 33,490 -1,185 -3.42 4,355 -13.93 0.0058
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,490 -1,185 4,355 1,034.0371
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,675 18,154 109.88 5,060 106.78 0.0081
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,521 7,012 73.74 2,447 136.43 0.0046
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,509 626 7.05 1,035 -0.10 0.0024
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,883 -75,959 -89.53 1,036 -84.82 0.0018
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 84,842 77,872 1,117.25 6,823 1,248.42 0.0127
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,970 -1,405 -16.78 506 -35.29 0.0010
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,375 -111,705 -93.03 782 -91.07 0.0014
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,080 109,262 1,010.00 8,755 825.48 0.0162
2018-11-13 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,818 -7,628 -41.35 946 -47.91 0.0015
2018-08-10 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,446 -18,894 -50.60 1,816 -59.17 0.0032
2018-05-11 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 37,340 27,817 292.10 4,448 267.60 0.0066
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,523 9,523 1,210 0.0018
2017-11-14 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -17,908 -100.00 0 -100.00
2017-08-14 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,908 17,908 1,430 0.0026
2017-02-09 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -10,047 -100.00 0 -100.00
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,047 151 1.53 681 24.04 0.0017
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,896 -240 -2.37 549 -13.68 0.0015
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,136 -1,350 -11.75 636 -41.17 0.0018
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,486 -6,963 -37.74 1,081 -27.06 0.0026
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,449 -4,942 -21.13 1,482 -47.15 0.0037
2015-08-13 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,391 18,473 375.62 2,804 445.53 0.0057
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,918 -363 -6.87 514 0.39 0.0010
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,281 5,281 512 0.0011
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-04-30 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 114,600 0.00 37,771 -17.96 n/a n/a n/a
2026-03-20 2025-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Put 114,600 46,038 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.